KR102108245B1 - 중간엽 간질 세포 및 이에 관련된 용도 - Google Patents

중간엽 간질 세포 및 이에 관련된 용도 Download PDF

Info

Publication number
KR102108245B1
KR102108245B1 KR1020147017312A KR20147017312A KR102108245B1 KR 102108245 B1 KR102108245 B1 KR 102108245B1 KR 1020147017312 A KR1020147017312 A KR 1020147017312A KR 20147017312 A KR20147017312 A KR 20147017312A KR 102108245 B1 KR102108245 B1 KR 102108245B1
Authority
KR
South Korea
Prior art keywords
cells
delete delete
msc
cell
mesenchymal stromal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147017312A
Other languages
English (en)
Korean (ko)
Other versions
KR20140127209A (ko
Inventor
로버트 란자
에린 앤 킴브렐
지안린 추
니콜라스 아더 코우리스
Original Assignee
아스텔라스 인스티튜트 포 리제너러티브 메디슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48536141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102108245(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스텔라스 인스티튜트 포 리제너러티브 메디슨 filed Critical 아스텔라스 인스티튜트 포 리제너러티브 메디슨
Publication of KR20140127209A publication Critical patent/KR20140127209A/ko
Application granted granted Critical
Publication of KR102108245B1 publication Critical patent/KR102108245B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/141—Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/08—Devices or methods enabling eye-patients to replace direct visual perception by another kind of perception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/54—Interprogram communication
    • G06F9/542—Event management; Broadcasting; Multicasting; Notifications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2218/00—Aspects of pattern recognition specially adapted for signal processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
KR1020147017312A 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도 Active KR102108245B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565358P 2011-11-30 2011-11-30
US61/565,358 2011-11-30
PCT/US2012/067464 WO2013082543A1 (en) 2011-11-30 2012-11-30 Mesenchymal stromal cells and uses related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207012502A Division KR102246369B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도

Publications (2)

Publication Number Publication Date
KR20140127209A KR20140127209A (ko) 2014-11-03
KR102108245B1 true KR102108245B1 (ko) 2020-05-08

Family

ID=48536141

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020147017312A Active KR102108245B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도
KR1020207012502A Active KR102246369B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도
KR1020237013378A Active KR102811933B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도
KR1020217010975A Active KR102525175B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207012502A Active KR102246369B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도
KR1020237013378A Active KR102811933B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도
KR1020217010975A Active KR102525175B1 (ko) 2011-11-30 2012-11-30 중간엽 간질 세포 및 이에 관련된 용도

Country Status (19)

Country Link
US (5) US8962321B2 (enExample)
EP (2) EP3449929B1 (enExample)
JP (5) JP2015500810A (enExample)
KR (4) KR102108245B1 (enExample)
CN (2) CN104136034B (enExample)
AU (4) AU2012345630A1 (enExample)
CA (1) CA2857545A1 (enExample)
CY (1) CY1122275T1 (enExample)
DK (1) DK2785359T3 (enExample)
ES (1) ES2690212T3 (enExample)
HR (1) HRP20181515T1 (enExample)
HU (1) HUE040566T2 (enExample)
LT (1) LT2785359T (enExample)
PL (1) PL2785359T3 (enExample)
PT (1) PT2785359T (enExample)
RS (1) RS57886B1 (enExample)
SI (1) SI2785359T1 (enExample)
TW (4) TWI812867B (enExample)
WO (1) WO2013082543A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712258B1 (en) * 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
CN112280739A (zh) 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
EP2872619B1 (en) 2012-07-11 2018-02-14 Imstem Biotechnology Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
EP3973967A1 (en) 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
DK2840132T3 (en) 2013-08-22 2017-02-20 Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts Universitätsmedizin Method of Manufacturing Constructed Heart Muscle (EHM)
CN106341978A (zh) * 2013-11-18 2017-01-18 高等教育联邦系统-匹兹堡大学 用于自身免疫疗法的树突细胞的基于微球的递送和离体操作
SG11201609993YA (en) * 2014-06-10 2016-12-29 Mesoblast Internat Sàrl Treatment of immune disorders
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
CN104232573B (zh) * 2014-09-11 2017-01-11 安沂华 一种生长培养基及其用途和培养脐带间充质干细胞的方法
US20160095885A1 (en) * 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104531613B (zh) * 2014-11-17 2017-12-19 中国农业科学院北京畜牧兽医研究所 Wip1敲除在促进小鼠骨髓间充质干细胞迁移中的应用
CN107257687B (zh) * 2014-12-23 2021-12-03 迈索布拉斯特国际有限公司 用于治疗心力衰竭的方法
EP4343331A3 (en) 2015-03-23 2024-06-19 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
PL3331994T3 (pl) 2015-08-05 2023-01-30 Cell Cure Neurosciences Ltd. Wytwarzanie komórek nabłonka barwnikowego siatkówki
AU2016308818B2 (en) 2015-08-18 2022-04-21 Astellas Institute For Regenerative Medicine Clinical formulations
CN108368479A (zh) * 2015-09-29 2018-08-03 细胞结构公司 细胞效能分析
WO2017060240A1 (en) * 2015-10-05 2017-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method and culture medium for ex vivo culturing of epidermis-derived stem cells
WO2017079621A1 (en) * 2015-11-04 2017-05-11 The Board Of Regents Of The University Of Texas System Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations
HK1254380A1 (zh) * 2015-11-24 2019-07-19 日本乐敦制药株式会社 包含脂肪组织来源基质细胞的肝病治疗剂及其制造方法
CN105326864A (zh) * 2015-11-30 2016-02-17 奥思达干细胞有限公司 一种治疗系统性红斑狼疮的干细胞制剂及其制备方法
US10383895B2 (en) * 2016-02-18 2019-08-20 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by T regulatory cells
CN105671000A (zh) * 2016-03-02 2016-06-15 深圳爱生再生医学科技有限公司 重组间充质干细胞及其制备方法和应用
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
IL264205B2 (en) * 2016-07-11 2023-12-01 Bonus Therapeutics Ltd Cellular compounds for tissue regeneration
CN106265899A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种组合物及其在制备改善慢性鼻炎的产品中的应用
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
CN106520686A (zh) * 2016-10-11 2017-03-22 海南博鳌龄迈迪精准医学研究院有限公司 脂肪间充质干细胞的培养方法
KR101971322B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
JP2019535691A (ja) * 2016-11-03 2019-12-12 エグゾステム バイオテック リミテッド 間葉系幹細胞集団、それらの生成物およびそれらの使用
CN106619721A (zh) * 2016-11-08 2017-05-10 中国人民解放军军事医学科学院野战输血研究所 一种增强细胞活性的新方法
CN106563161A (zh) * 2016-11-08 2017-04-19 华南生物医药研究院 可用于美容的新型药物组合剂
CN106581760A (zh) * 2016-11-08 2017-04-26 华南生物医药研究院 增强细胞活性的特殊处理方法
KR102390909B1 (ko) * 2016-12-19 2022-04-26 주식회사 파이안바이오테크놀로지 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703058D0 (en) * 2017-02-24 2017-04-12 Ucl Business Plc Biomarkers
JP7102397B2 (ja) 2017-04-03 2022-07-19 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
WO2018207918A1 (ja) * 2017-05-12 2018-11-15 国立大学法人 東京医科歯科大学 移植効率を向上させる間葉系幹細胞の純化方法
JP7712643B2 (ja) * 2017-06-19 2025-07-24 国立大学法人東北大学 表皮水疱症の治療剤
CN107490701B (zh) * 2017-08-17 2021-09-14 上海集技生物技术有限公司 一种基于局部照射的全身性骨损伤模型的建立及病理机制分析的方法
CN107714726A (zh) 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
CN109069543B (zh) * 2017-10-16 2020-02-18 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
WO2019086912A1 (en) * 2017-11-06 2019-05-09 King's College London Therapeutic substances, their preparation and diagnostic procedure
KR102095628B1 (ko) 2018-01-05 2020-04-01 재단법인 아산사회복지재단 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물
CN111712565A (zh) * 2018-02-16 2020-09-25 奈科斯特细胞制药有限公司 同种异体组合物
WO2019171386A1 (en) * 2018-03-07 2019-09-12 The Medical Research Infrastructure And Health Services Fund Of The Tel-Aviv Medical Center Compositions and methods for treating age-related macular degeneration
CA3103043A1 (en) * 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
CN109082409A (zh) * 2018-09-14 2018-12-25 四川新生命干细胞科技股份有限公司 一种组织修复能力强的脂肪干细胞分离培养及筛选方法
CN109182262A (zh) * 2018-09-25 2019-01-11 深圳市五零生命科技有限公司 一种间充质干细胞无血清培养基
JP2022513113A (ja) * 2018-11-26 2022-02-07 マサチューセッツ インスティテュート オブ テクノロジー 免疫寛容のための組成物および方法
CN109342739A (zh) * 2018-11-27 2019-02-15 上海科医联创生物科技有限公司 一种鉴定间充质干细胞纯度的方法
CN109609584A (zh) * 2018-12-10 2019-04-12 天津长和生物技术有限公司 间充质干细胞免疫调节能力的检测方法
CN113544261B (zh) * 2019-02-27 2024-10-01 武田药品工业株式会社 用于同种异体疗法的改良的干细胞群
MX2021010739A (es) * 2019-03-12 2021-12-15 Boehringer Ingelheim Veterinary Medicine Belgium Celulas madre mesenquimales inmunomoduladoras.
KR20210138655A (ko) 2019-03-14 2021-11-19 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 근위축성 측삭 경화증의 치료용 의약 조성물
CN114787340B (zh) 2019-07-26 2025-02-25 布瑞克斯奥根株式会社 诱导多能干细胞来源间充质干细胞前体细胞及其制备方法
CN110305839A (zh) * 2019-08-02 2019-10-08 陕西佰傲干细胞再生医学有限公司 间充质干细胞无血清培养基
US20220280572A1 (en) 2019-08-28 2022-09-08 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
MX2022002418A (es) 2019-08-28 2022-03-22 Astellas Inst For Regenerative Medicine Composiciones y metodos de tratamiento de enfermedades vasculares.
CN110564674B (zh) * 2019-09-29 2021-05-11 广东工业大学 一种干细胞铺底工作液及其应用
WO2021072595A1 (zh) * 2019-10-14 2021-04-22 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在治疗听力障碍上的医药用途
RU2740152C1 (ru) * 2020-01-09 2021-01-13 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН) Способ активации пролиферативного ответа фибробластоподобных клеток стромально-васкулярной фракции жировой ткани
WO2021169017A1 (zh) * 2020-02-25 2021-09-02 上海大学 间充质干细胞在治疗重症covid19肺炎中的用途
US20230158076A1 (en) * 2020-04-13 2023-05-25 National University Corporation Tokai National Higher Education And Research System Agent for increasing cd25-positive regulatory t cells in kidneys
CN115701285A (zh) * 2020-04-28 2023-02-07 菲克特生物科学股份有限公司 间充质干细胞疗法
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111518761B (zh) * 2020-05-25 2022-04-29 青岛瑞思德生物科技有限公司 一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法
WO2022004938A1 (ko) * 2020-06-30 2022-01-06 주식회사 미래셀바이오 유사 중간엽 줄기세포의 제조방법
EP3945133A1 (en) * 2020-07-29 2022-02-02 Georg-August-Universität Göttingen Mass production of human pluripotent stem cell derived cardiac stromal cell
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US20230405051A1 (en) * 2020-10-22 2023-12-21 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for prevention or treatment of rheumatoid arthritis, comprising, as active ingredient, stem cells having expression of specific genes increased or decreased therein
US20240366676A1 (en) * 2021-05-07 2024-11-07 Sungkwang Medical Foundation Mesenchymal stem cells having enhanced osteogenic differentiation capacity, and use thereof
EP4366744A1 (en) * 2021-07-08 2024-05-15 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of chronic gingivostomatitis
CN113717972B (zh) * 2021-08-16 2022-07-01 南通市肿瘤医院 MYADM靶向的siRNA及其应用
JP2024536534A (ja) * 2021-10-12 2024-10-04 メカノジェニックインク 間葉系幹細胞を用いた抗老化組成物及びその方法
EP4476327A1 (en) * 2022-02-07 2024-12-18 SmartCella Solutions AB Methods and compositions for generating human induced mesenchymal stem cells
CN114984051A (zh) * 2022-06-27 2022-09-02 广州惠善医疗技术有限公司 间充质干细胞在制备治疗炎症及免疫相关疾病的药物中的应用
WO2024007038A2 (en) * 2022-07-01 2024-01-04 Northwestern University Compositions and methods for the treatment of intestinal inflammation
EP4558154A1 (en) 2022-07-18 2025-05-28 Astellas Institute for Regenerative Medicine Methods of treating brain injury
CN115305234B (zh) * 2022-09-28 2023-01-17 呈诺再生医学科技(北京)有限公司 一种制备间充质干细胞的方法、间充质干细胞和应用
WO2024158058A1 (ja) * 2023-01-27 2024-08-02 株式会社Rainbow 自動培養装置における細胞増殖制御方法
TW202434721A (zh) * 2023-02-14 2024-09-01 國立大學法人山口大學 細胞群、三維細胞培養體、醫藥組成物、胞泌體及製作此細胞群的方法
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法
CN117210528B (zh) * 2023-09-12 2024-08-20 长沙干细胞与再生医学工业技术研究院有限公司 一种综合评估间充质干细胞免疫调控能力的方法
WO2025084581A1 (ko) * 2023-10-18 2025-04-24 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포를 포함하는 복막 섬유증의 개선, 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232777A1 (en) * 2006-03-01 2009-09-17 Evy Lundgren-Akerlund Expansion and Differentiation of Mesenchymal Stem Cells
US20110129918A1 (en) * 2009-11-30 2011-06-02 Shih-Chieh Hung Method for expanding mesenchymal stem cells in low-density and hypoxic culture

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6416581A (en) * 1987-07-09 1989-01-20 Rikagaku Kenkyusho Frozen animal cell and production thereof
US5128259A (en) 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
EP0739412B1 (en) 1993-12-23 2002-02-27 Infigen, Inc. ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
WO1998033891A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
WO1998053048A1 (en) 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6429012B1 (en) 1997-10-06 2002-08-06 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
JP4526186B2 (ja) 1998-06-08 2010-08-18 オシリス セラピューティクス，インコーポレイテッド 造血幹細胞を試験管内で維持する方法と組成物
US6361998B1 (en) 1998-06-25 2002-03-26 Hemosol Inc. Efficient culture of stem cells for the production of hemoglobin
EP1270719A3 (en) 1998-08-24 2003-06-25 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
BR0014864A (pt) 1999-10-15 2002-11-19 Advanced Cell Tech Inc Métodos de produzir células progenitoras diferenciadas e células tronco embriÈnicas defeituosas em linhagem
WO2001036589A2 (en) 1999-11-17 2001-05-25 University Of Rochester Human ex vivo immune system
WO2001050848A2 (en) 2000-01-07 2001-07-19 Oregon Health And Science University Clonal propagation of primate offspring by embryo splitting
EP1248834A4 (en) 2000-01-21 2004-03-17 Univ Johns Hopkins CELLS FROM HUMAN EMBRYOID BODIES
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
AU8617301A (en) 2000-08-01 2002-02-13 Yissum Res Dev Co Directed differentiation of embryonic cells
AU9109201A (en) 2000-09-18 2002-03-26 Organogenesis Inc Methods for treating a patient using a bioengineered flat sheet graft prostheses
EP1364197B1 (en) 2001-01-29 2010-04-14 Ivan N. Rich ATP-based assay for the determination of the proliferation status of hematopoietic stem and progenitor cells
WO2002078449A2 (en) 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
KR20020083634A (ko) 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
WO2003038072A1 (en) 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
CA2465173C (en) 2001-11-02 2010-04-20 Wisconsin Alumni Research Foundation Endothelial cells derived from primate embryonic stem cells
ATE438708T1 (de) * 2001-11-15 2009-08-15 Childrens Medical Center Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
EP1463803B1 (en) 2001-12-07 2018-02-14 Asterias Biotherapeutics, Inc. Hematopoietic cells from human embryonic stem cells
US7491389B2 (en) * 2002-03-21 2009-02-17 University Of Florida Reasearch Foundation, Inc. Modulating angiogenesis
AU2003248609A1 (en) 2002-07-12 2004-02-02 Agency For Science, Technology And Research Hemangioblast progenitor cells
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
AR047712A1 (es) 2002-09-07 2006-02-15 Royal Veterinary College Metodo de tratamiento de una lesion de tejido esqueletico blando natural administrando una composicion de celulas madre mesenquimatosas
WO2004029200A2 (en) 2002-09-26 2004-04-08 Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
WO2004029231A1 (en) 2002-09-26 2004-04-08 Institut National De La Sante Et De La Recherche Medicale Compositions and methods for amplification of human stem cells
AU2003287521A1 (en) 2002-11-06 2004-06-03 Carlos J. Piniella Pluripotent cells from monocytes, and methods of making and using pluripotent cells
US20040156878A1 (en) 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
WO2004098285A2 (en) 2003-05-08 2004-11-18 Cellartis Ab Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
US20040229350A1 (en) 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
US20070141703A1 (en) 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture
EP1708757A4 (en) 2003-12-19 2007-01-17 Viacell Inc USE OF PLURIPOTENTIAL CELLS TAKEN FROM HUMAN CORDIAL BLOOD BLOOD FOR THE TREATMENT OF DISEASE
CN1286970C (zh) 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
NZ548623A (en) 2004-01-02 2010-04-30 Advanced Cell Tech Inc Novel culture systems for ex vivo development of stem cells in telolecithal or eutelolecithal eggs
KR100535326B1 (ko) 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
SG188122A1 (en) 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA2554094A1 (en) 2004-02-09 2005-08-25 Indiana University Research And Technology Corporation Isolation, expansion and use of clonogenic endothelial progenitor cells
EP2298861B1 (en) 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP1735429A4 (en) 2004-03-31 2008-06-11 Newlink Genetics Corp METHOD AND COMPOSITIONS FOR OBTAINING EMBRYONAL STEM CELLS OF ABSTINENT HEMATOPOETIC STEM CELLS AND USES THEREOF
EP1743023A1 (en) 2004-05-07 2007-01-17 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
JP4980211B2 (ja) * 2004-05-12 2012-07-18 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 細胞単離方法
EP1753859B1 (en) 2004-06-04 2014-07-30 Université Pierre et Marie Curie (Paris 6) A method for producing red blood cells
CA2571849A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having rna virus transferred thereinto
US20080260694A1 (en) 2004-09-24 2008-10-23 Angioblast Systems, Inc. Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof
WO2006050330A2 (en) 2004-11-01 2006-05-11 Wisconsin Alumni Research Foundation Platelets from stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US20080166751A1 (en) 2005-02-23 2008-07-10 Takayuki Asahara Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells
WO2006090882A1 (ja) 2005-02-23 2006-08-31 Foundation For Biomedical Research And Innovation 血管内皮前駆細胞の生体外増幅方法
JP2006230316A (ja) * 2005-02-25 2006-09-07 Japan Health Science Foundation 瘢痕のない創傷治癒能を有する細胞およびその調製方法
CA2601197C (en) 2005-03-17 2017-06-06 Ucl Biomedica Plc Method
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
WO2006130504A2 (en) 2005-05-27 2006-12-07 Advanced Cell Technology, Inc. Methods for identifying ligands for stem cells and cells derived therefrom
CA2610243C (en) 2005-06-01 2016-11-15 Wisconsin Alumni Research Foundation Method of forming dendritic cells from embryonic stem cells
WO2007005595A1 (en) 2005-07-05 2007-01-11 The New England Medical Center Hospitals, Inc. Pregnancy-associated progenitor cells
CA2659945C (en) 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
EP1909565A2 (en) 2005-08-03 2008-04-16 Interface Multigrad Technology (IMT) Ltd. Somatic cells for use in cell therapy
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
JP2007089432A (ja) 2005-09-27 2007-04-12 Reprocell Inc 幹細胞由来血小板産生増加法
PT1941027E (pt) 2005-09-28 2014-10-09 Ipd Therapeutics B V Métodos e meios para proliferação de células estaminais e subsequente geração e expansão de células progenitoras, bem como produção de células efectoras como produtos terapêuticos clínicos
WO2007047894A2 (en) 2005-10-20 2007-04-26 Advanced Cell Technology, Inc. Totipotent, nearly totipotent or pluripotent mammalian cells homozygous or hemizygous for one or more histocompatibility antigen genes
CA2626152A1 (en) 2005-10-24 2007-05-03 Agency For Science, Technology And Research Methods of specifying mesodermal, endodermal and mesoendodermal cell fates
WO2007062198A1 (en) 2005-11-21 2007-05-31 Advanced Cell Technology, Inc. Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
ES2415855T3 (es) 2006-01-13 2013-07-29 Osiris Therapeutics, Inc. Células troncales mesenquimatosas que expresan el receptor de TNF
WO2007095064A2 (en) 2006-02-09 2007-08-23 Wisconsin Alumni Research Foundation ERYTHROID CELLS PRODUCING ADULT-TYPE β-HEMOGLOBIN GENERATED FROM HUMAN EMBRYONIC STEM CELLS
WO2007093412A2 (en) 2006-02-16 2007-08-23 Fondazione Centro San Raffaele Del Monte Tabor Skeletal muscle periangioblasts and cardiac mesoangioblasts, method for isolation and uses thereof
CN101045915A (zh) 2006-03-29 2007-10-03 旭日干 一种卵母细胞生发泡移植技术
CN101045914A (zh) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
NZ572842A (en) 2006-04-14 2012-01-12 Advanced Cell Tech Inc Hemangio-colony forming cells
EP3712258B1 (en) 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
AU2013201444B2 (en) 2006-04-14 2015-01-22 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
KR100791487B1 (ko) * 2006-05-29 2008-01-03 연세대학교 산학협력단 제대혈로부터 간엽줄기세포의 분리 및 배양 방법
US20070298496A1 (en) 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
EP2054506A1 (en) 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
EP2578081B1 (en) 2006-10-11 2016-03-09 The General Hospital Corporation Compositions, methods, and devices for treating liver disease
WO2008067142A2 (en) 2006-11-08 2008-06-05 Wisconsin Alumni Research Foundation In vitro differentiation of hematopoietic cells from primate embryonic stem cells
EP2088190A4 (en) 2006-11-09 2011-01-05 Japan Government METHOD FOR THE CULTURE AND PASSING OF AN EMBRYONAL PRIMATIVE STEM CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF THE EMBRYONAL STEM CELL
DE102006054041B3 (de) 2006-11-16 2008-05-08 Pierburg Gmbh Regelvorrichtung für eine Verbrennungskraftmaschine
EP3190178A1 (en) 2007-02-23 2017-07-12 Astellas Institute for Regenerative Medicine Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells
BRPI0811906A2 (pt) 2007-05-24 2014-11-18 Apceth Gmbh & Co Kg Composições e métodos relacionados a célula-tronco cd34
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2008151386A1 (en) 2007-06-15 2008-12-18 Australian Stem Cell Centre Ltd Megakaryocyte differentiation
US9095562B2 (en) 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
ES2923016T3 (es) 2007-08-06 2022-09-22 Mesoblast Inc Células precursoras mesenquimales TNAP+ para el tratamiento de enfermedades del tejido conectivo
KR101039235B1 (ko) * 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
US20110236971A2 (en) * 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
ES2764473T3 (es) 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
US20100304480A1 (en) 2007-10-19 2010-12-02 Goodell Margaret A Hematopoietic Fingerprints: Methods of Use
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
US8685728B2 (en) 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
US10046011B2 (en) 2008-01-31 2018-08-14 Rutgers, The State University Of New Jersey Compositions for inducing or suppressing an immune response
JP5728234B2 (ja) 2008-02-15 2015-06-03 ボーン・セラピューティクス 骨関節疾患の治療又は予防において使用するための医薬組成物
WO2009104825A1 (en) 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
EP3441462A1 (en) 2008-05-06 2019-02-13 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
CN112280739A (zh) 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
KR20110013450A (ko) 2008-05-07 2011-02-09 본 테라퓨틱스 소시에테아노님 간엽 줄기 세포 및 골-형성 세포
EP2321408A4 (en) * 2008-08-04 2013-04-17 Allocure Inc MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE
CN102144028B (zh) 2008-09-03 2017-12-26 中胚有限公司 造血前体的扩增
FR2938947B1 (fr) 2008-11-25 2012-08-17 A Volute Procede de traitement du signal, notamment audionumerique.
EP2221362A1 (en) 2009-02-19 2010-08-25 Naturin GmbH & Co Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
CA2756670A1 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
JP2010252778A (ja) * 2009-04-02 2010-11-11 Shizui Bank Kk 歯髄由来間葉系幹細胞の分離方法及び分離した幹細胞並びにそれらを用いた肝細胞系譜への分化
KR101788885B1 (ko) 2009-07-09 2017-10-20 타이제닉스, 에스.에이.유. 세포 요법에 사용하기 위한 방법 및 조성물
AU2010303469A1 (en) * 2009-10-06 2012-05-03 The Cohen Mcniece Foundation Preparation and use of stromal cells for treatment of cardiac diseases
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
US20110123498A1 (en) 2009-10-30 2011-05-26 Christof Westenfelder Mesenchymal stromal cell populations and methods of using same
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
RU2012127811A (ru) 2009-12-04 2014-01-10 Стем Селл Энд Ридженерэйтив Медсин Интернэшнл, Инк. Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток
KR20190142424A (ko) 2009-12-04 2019-12-26 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
EP2531593A4 (en) * 2010-02-02 2013-08-28 Univ Rochester PROCESS FOR THE ISOLATION AND CULTIVATION OF MESENCHYMAL STEM CELLS
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
JP5804385B2 (ja) 2010-03-10 2015-11-04 株式会社ツーセル 間葉系幹細胞を含む細胞製剤及びその製造方法
WO2011124741A1 (es) 2010-04-08 2011-10-13 Fundación Progreso Y Salud Uso de un medio de cultivo condicionado por células madre mesenquimales para la diferenciación de células madre pluripotentes humanas
KR101330327B1 (ko) 2010-05-07 2013-11-14 한국생명공학연구원 줄기세포로부터 생성된 배아체를 대량 증식 및 유지하는 방법
CN103118691B (zh) 2010-08-23 2016-08-24 康干细胞生物科技有限公司 预防和治疗免疫病变和炎性疾病的包括用nod2激动剂处理的干细胞或其培养物的药物组合物
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
KR101477016B1 (ko) 2012-01-19 2014-12-29 (주)차바이오텍 인간 배아줄기세포 유래 혈관주위 전구세포의 제조방법 및 이를 포함하는 세포치료 조성물
CN104471059B (zh) * 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CN105008521B (zh) 2012-12-14 2018-11-20 罗格斯新泽西州立大学 调节干细胞的免疫调节作用的方法
CA2901653C (en) 2013-03-01 2019-01-08 Gunther Eissner Protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells
KR101669124B1 (ko) 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
JP6615753B2 (ja) 2013-10-04 2019-12-04 レジニアス リミテッド 細胞療法のためのバイオマーカー
SG11201606832YA (en) 2014-02-18 2016-09-29 Massachusetts Inst Technology Biophysically sorted osteoprogenitors from culture expanded bone marrow derived mesenchymal stromal cells (mscs)
SG11201609993YA (en) 2014-06-10 2016-12-29 Mesoblast Internat Sàrl Treatment of immune disorders
JP6459257B2 (ja) 2014-07-08 2019-01-30 富士ゼロックス株式会社 画像形成装置
US20170204151A1 (en) 2014-07-28 2017-07-20 Darwin J. Prockop Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders
WO2017038784A1 (ja) 2015-08-28 2017-03-09 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞及びその調製方法、ｒｏｒ１陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる疾患の予防又は治療方法
EP3369810A4 (en) 2015-10-27 2019-05-01 Kaneka Corporation METHOD FOR PRODUCING CELL POPULATION WITH MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS, CELL POPULATION AND PHARMACEUTICAL COMPOSITION
JP6890549B2 (ja) 2015-12-03 2021-06-18 タカラバイオ株式会社 間葉系幹細胞の製造方法
CA3017772C (en) 2016-03-16 2023-02-21 Cynata Therapeutics Limited Colony forming medium and use thereof
JP7108537B2 (ja) 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
KR101816246B1 (ko) 2016-09-07 2018-01-08 에스씨엠생명과학 주식회사 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물
CN110121553A (zh) 2016-10-27 2019-08-13 纽约哥伦比亚大学董事会 免疫抑制性间充质细胞及其形成方法
EP3551748B1 (en) 2016-12-12 2022-07-13 Health and Biotech France (H&B France) Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof
US20200056156A1 (en) 2017-04-03 2020-02-20 Kaneka Corporation Cell population comprising mesenchymal stem cells, method for producing the same, and pharmaceutical composition
JP7102397B2 (ja) 2017-04-03 2022-07-19 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
EP3619294A1 (en) 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232777A1 (en) * 2006-03-01 2009-09-17 Evy Lundgren-Akerlund Expansion and Differentiation of Mesenchymal Stem Cells
US20110129918A1 (en) * 2009-11-30 2011-06-02 Shih-Chieh Hung Method for expanding mesenchymal stem cells in low-density and hypoxic culture

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Autoimmunity reviews, Vol.10, no.7, pp.410-415, (2011, 05)*
Cell Stem Cell. (2010)*
PLoS medicine, Vol.2, no.6, pp.e161, (2005)*
PLoS MEDICINE, Volume 2, Issue 6, (2005)*

Also Published As

Publication number Publication date
AU2017239526A1 (en) 2017-10-26
CN108478599A (zh) 2018-09-04
AU2022202639A1 (en) 2022-05-12
JP7777430B2 (ja) 2025-11-28
EP2785359A4 (en) 2015-11-11
CA2857545A1 (en) 2013-06-06
US20210182552A1 (en) 2021-06-17
KR20140127209A (ko) 2014-11-03
EP2785359A1 (en) 2014-10-08
JP2022027796A (ja) 2022-02-14
HK1202798A1 (en) 2015-10-09
TW201331365A (zh) 2013-08-01
KR102811933B1 (ko) 2025-05-23
TW201815399A (zh) 2018-05-01
TWI698527B (zh) 2020-07-11
TW202344258A (zh) 2023-11-16
US8962321B2 (en) 2015-02-24
DK2785359T3 (en) 2018-10-29
JP6526130B2 (ja) 2019-06-05
EP3449929A1 (en) 2019-03-06
AU2012345630A1 (en) 2014-07-17
US12097223B2 (en) 2024-09-24
JP6983195B2 (ja) 2021-12-17
KR20200051827A (ko) 2020-05-13
KR102246369B1 (ko) 2021-04-29
CN104136034A (zh) 2014-11-05
HUE040566T2 (hu) 2019-03-28
KR20210044904A (ko) 2021-04-23
US20250090590A1 (en) 2025-03-20
CY1122275T1 (el) 2020-07-31
EP2785359B1 (en) 2018-08-29
JP2015500810A (ja) 2015-01-08
CN104136034B (zh) 2018-04-24
TWI812867B (zh) 2023-08-21
TW202037373A (zh) 2020-10-16
RS57886B1 (sr) 2019-01-31
KR102525175B1 (ko) 2023-04-21
AU2017239526B2 (en) 2019-08-15
JP2019142958A (ja) 2019-08-29
EP3449929B1 (en) 2025-11-19
AU2019264631A1 (en) 2019-12-05
LT2785359T (lt) 2018-11-12
PT2785359T (pt) 2018-11-06
ES2690212T3 (es) 2018-11-19
JP2024067032A (ja) 2024-05-16
AU2019264631B2 (en) 2022-01-20
US20130183272A1 (en) 2013-07-18
CN108478599B (zh) 2022-08-02
TWI698242B (zh) 2020-07-11
HRP20181515T1 (hr) 2018-11-16
JP2018027954A (ja) 2018-02-22
WO2013082543A1 (en) 2013-06-06
US20160038543A1 (en) 2016-02-11
KR20230059838A (ko) 2023-05-03
AU2022202639B2 (en) 2025-06-12
PL2785359T3 (pl) 2018-12-31
SI2785359T1 (sl) 2018-11-30
US20170252374A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
JP7777430B2 (ja) 間葉系間質細胞及びその関連用途
US20220160778A1 (en) Mesenchymal stromal cells and uses related thereto
HK40003685A (en) Mesenchymal stromal cells and uses related thereto
TW202537630A (zh) 利用血管母細胞產生間葉基質細胞之方法
HK1202798B (en) Mesenchymal stromal cells and uses related thereto

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140624

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190122

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190722

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200129

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200428

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200429

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200504

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230413

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240409

Start annual number: 5

End annual number: 5